Protocol Ledger

NCT07759154 · Phase III · RECRUITING

A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

Interventional Phase III clinical trial protocol NCT07759154 sponsored by Otsuka Pharmaceutical Development & Commercialization in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-01 Enrollment: 80 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07759154
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07759154
Protocol FieldVerified Registry Value
NCT IdentifierNCT07759154
Consolidated Lead SponsorOtsuka Pharmaceutical Development & Commercialization
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment80 participants (ESTIMATED)
Registered Start Date2026-09-01
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI